Article summary
This week's edition of Life Sciences weekly highlights includes analysis of Lord O’Shaughnessy’s UK commercial clinical trials review and the government’s response by Harriet Hanks and Emily Fowler at Freshfields Bruckhaus Deringer LLP, and news on the UK government’s response to Professor Dame Angela McLean’s recommendations, as well as Law360 news republish about Glaxo Group Ltd inhaler revival application and Sandoz AG claim to invalidate prostate cancer drug patent, news on the Unified Patent System and the Unified Patent Court which has opened on 1 June 2023. This edition also includes news on a sentence in relation to the illegal supply of £1.2m of prescription drugs, the publication of Commission Horizontal block exemption regulations (HBERs), MLex analysis of the new EU-US Data Privacy Framework, EFPIA’s recommendations on how to improve access to digital therapeutics (DTx), collaboration between WHO and the Commission to develop digital health system, and a new global minimised risk of antimicrobial resistance (AMR) certification launched by the British Standards Institution (BSI), among other stories.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial
Access this content for free with a 7 day trial of LexisNexis and benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 42 practice areas
Get your quote today and take step closer to being able to benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 36 practice areas
Get a quote for Lexis+
* denotes a required field
CONTACT US
